ORANO // Annual Activity Report 2024

2 SITUATION AND ACTIVITIES OF THE COMPANY AND ITS SUBSIDIARIES DURING THE PAST FINANCIAL YEAR The group’s businesses

2.3.4 Other activities of Orano

Orano’s other activities include the other cross-business functions, as well as Nuclear Medicine.

This innovative approach is called targeted alpha-therapy. It can recognize and destroy cancer cells selectively, limiting the impact on surrounding healthy cells. Orano Med’s ambition is to develop effective and targeted anti cancer therapies in two strategic areas: ● developing innovative treatments using Orano Med’s lead-212 through scienti fi c partnerships or 100% Orano Med projects; and ● building the production plants to produce high-purity lead-212 and thus meet the needs of current clinical development and future marketing of drugs.

Nuclear Medicine Orano’s Nuclear Medicine business is mainly carried out by Orano Med, its medical subsidiary. Orano Med has developed a unique process to extract and produce lead-212 ( 212 Pb), which is a particularly rare alpha-emitting radioactive isotope, at a very high degree of purity. Orano Med is developing promising treatments that combine lead-212 with various biological molecules that target cancer cells.

ORANO MED’S ONCOLOGY R&D PIPELINE

Program

Indication (target)

Discovery

PoC

Pre-IND Phase 1 Phase 2/3

Partners

Neuroendocrine tumors

AlphaMedix TM

Solid tumors (breast and prostate cancer)

212 Pb-GRPR

212 Pb-PSMA

Prostate cancer

Solid tumors

212 Pb-PRIT

212 Pb DARPin DLL3 / MP0712

Small-cell lung cancer

Undisclosed target

212 Pb DARPin

Phage display platform

212 Pb PRRT

Undisclosed target

Phage display platform

Undisclosed target

212 Pb-PRRT

Undisclosed

212 Pb-PRRT

Several targets

Undisclosed

212 Pb TAT

Several targets

Source: Orano

44

Orano - Annual Activity Report 2024